Ann: Response to ASX Price & Volume Query, page-4

From the response....
"In addition to the above, ANP’s technology collaboration partner Ionis Pharmaceuticals Inc, a world leader in antisense drug development and commercialisation has recently
announced a number of positive developments in regard to the commercial and scientific progress of its antisense technology platform, including a $1 billion investment by Biogen Idec, representing one of the most significant discovery stage collaborations in the industry and a favourable FDA advisory committee recommendation for one of Ionis’ drugs to be approved by the FDA for the US market. This can be interpreted as further validation for the antisense technology platform upon which ANP’s product pipeline is based".